NCT07203118View on ClinicalTrials.gov

A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,444

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

February 28, 2030

Conditions
Chronic Hepatitis B
Interventions
DRUG

HTS 20mg

Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.

DRUG

HTS 30mg

Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.

DRUG

HTS 40mg

Once daily, administered concomitantly with one TAF placebo tablet per dose, taken once daily with or within 30 minutes after a meal.

DRUG

TAF 25mg

Once daily, administered concomitantly with one HTS placebo tablet per dose, taken once daily with or within 30 minutes after a meal.

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Jilin

All Listed Sponsors
lead

Xi'an Xintong Pharmaceutical Research Co.,Ltd.

OTHER